Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Miracil D: An Inhibitor of Ribonucleic Acid Synthesis in Bacillus subtilis

I. BERNARD WEINSTEIN, ROBIN CHERNOFF, IRENE FINKELSTEIN and ERICH HIRSCHBERG
Molecular Pharmacology November 1965, 1 (3) 297-305;
I. BERNARD WEINSTEIN
Departments of Medicine and Biochemistry, Columbia University College of Physicians and Surgeons, and Department of Medicine, Francis Delafield Hospital, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROBIN CHERNOFF
Departments of Medicine and Biochemistry, Columbia University College of Physicians and Surgeons, and Department of Medicine, Francis Delafield Hospital, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IRENE FINKELSTEIN
Departments of Medicine and Biochemistry, Columbia University College of Physicians and Surgeons, and Department of Medicine, Francis Delafield Hospital, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ERICH HIRSCHBERG
Departments of Medicine and Biochemistry, Columbia University College of Physicians and Surgeons, and Department of Medicine, Francis Delafield Hospital, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Miracil D (1-diethylaminoethylamino-4-methyl-10-thiaxanthenone) is effective against schistosomiasis in man and against experimental tumors in mice, but its mode of action had not been defined. The present study indicates that at 20 µg/ml the drug arrests the growth of Bacillus subtilis. This antibacterial action is also exhibited by a tumor-inhibitory derivative, but not by a derivative devoid of carcinostatic activity. Incubation of B. subtilis with 14C-uracil, thymidine, or leucine in the presence of 20 µg/ml of Miracil D indicated a complete inhibition of RNA synthesis, immediate but less severe inhibition of protein synthesis, and no inhibition of DNA synthesis. The drug has absorption maxima at 442 and 330 mµ. In the presence of native DNA there is quenching of absorption at these wavelengths, with a shift in the maxima to 450 and 337 mµ. In heat-denaturation studies, Miracil D raised the Tm of DNA by 15°. Similar studies gave evidence for a lesser affinity between Miracil D and sRNA. These results indicate that the major action of this drug in B. subtilis is to complex with DNA, thereby blocking DNA-dependent RNA synthesis.

ACKNOWLEDGMENT This work was supported in part by U.S. Public Health Service research grant (R10 CA 02332) and training grant (T4 CA 5011) from the National Cancer Institute. One of us (I.B.W.) is a Career Scientist of the New York City Health Research Council (I-190).

  • Copyright ©, 1965, by Academic Press Inc.

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 1, Issue 3
1 Nov 1965
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Miracil D: An Inhibitor of Ribonucleic Acid Synthesis in Bacillus subtilis
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
Citation Tools
Research ArticleArticle

Miracil D: An Inhibitor of Ribonucleic Acid Synthesis in Bacillus subtilis

I. BERNARD WEINSTEIN, ROBIN CHERNOFF, IRENE FINKELSTEIN and ERICH HIRSCHBERG
Molecular Pharmacology November 1, 1965, 1 (3) 297-305;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Miracil D: An Inhibitor of Ribonucleic Acid Synthesis in Bacillus subtilis

I. BERNARD WEINSTEIN, ROBIN CHERNOFF, IRENE FINKELSTEIN and ERICH HIRSCHBERG
Molecular Pharmacology November 1, 1965, 1 (3) 297-305;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Operational Models for Receptors with Multiple Agonist Sites
  • BODIPY-cyclopamine Binding to Nluc-SMO
  • Characterization and optimization of the novel TRPM2 antagonist tatM2NX
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics